Francis Collin’s promise to increase ME/CFS funding, however, caused a seismic shift in the drugs outlook. Hemispherx Biopharma’s board quickly fired its controversial, longtime CEO, William Carter, and appointed Thomas Equels to the post.
In an interview Equels said he had one and only one priority: get FDA approval for Ampligen. Find out more in a Simmaron Research Foundation sponsored post:
Register for our free ME/CFS, fibromyalgia, and long COVID blogs here.